-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Individual Investors Who Hold 57% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Gained 8.0%, Institutions Profited as Well
Individual Investors Who Hold 57% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Gained 8.0%, Institutions Profited as Well
A look at the shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are individual investors with 57% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
Following a 8.0% increase in the stock price last week, individual investors profited the most, but institutions who own 40% stock also stood to gain from the increase.
In the chart below, we zoom in on the different ownership groups of Aurinia Pharmaceuticals.
Check out our latest analysis for Aurinia Pharmaceuticals
NasdaqGM:AUPH Ownership Breakdown September 14th 2022What Does The Institutional Ownership Tell Us About Aurinia Pharmaceuticals?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
We can see that Aurinia Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Aurinia Pharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story.
NasdaqGM:AUPH Earnings and Revenue Growth September 14th 2022Hedge funds don't have many shares in Aurinia Pharmaceuticals. Looking at our data, we can see that the largest shareholder is BlackRock, Inc. with 5.5% of shares outstanding. ILJIN SNT Co., Ltd is the second largest shareholder owning 4.0% of common stock, and FMR LLC holds about 3.4% of the company stock.
A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of Aurinia Pharmaceuticals
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
We can report that insiders do own shares in Aurinia Pharmaceuticals Inc.. The insiders have a meaningful stake worth US$18m. Most would see this as a real positive. If you would like to explore the question of insider alignment, you can click here to see if insiders have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a substantial 57% stake in Aurinia Pharmaceuticals, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Aurinia Pharmaceuticals has 1 warning sign we think you should be aware of.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看看金色制药公司(纳斯达克:AUPH)的股东就能知道哪个集团最有权势。而持有这块蛋糕最大份额的群体是拥有57%股权的个人投资者。换句话说,该集团面临着最大的上行潜力(或下行风险)。
继上周股价上涨8.0%后,个人投资者获利最多,但持有40%股票的机构也将从涨幅中受益。
在下面的图表中,我们放大了aurinia PharmPharmticals的不同所有权组。
查看我们对Auinia制药公司的最新分析
NasdaqGM:AUPH所有权明细2022年9月14日机构所有权告诉了我们关于金色制药的什么?
机构投资者通常将自己的回报与经常跟踪的指数的回报进行比较。因此,他们通常确实会考虑收购被纳入相关基准指数的较大公司。
我们可以看到,aurinia PharmPharmticals确实有机构投资者;他们持有公司很大一部分股票。这表明在专业投资者中有一定的可信度。但我们不能仅仅依靠这一事实,因为机构有时会做出糟糕的投资,就像每个人一样。当多家机构持有一只股票时,它们总是面临“拥挤交易”的风险。当这样的交易出错时,多方可能会竞相快速抛售股票。在一家没有增长历史的公司,这一风险更高。你可以在下面看到Auinia制药公司的历史收益和收入,但请记住,故事中总是有更多的东西。
NasdaqGM:AUPH收益和收入增长2022年9月14日对冲基金在aurinia PharmPharmticals的股份并不多。看我们的数据,我们可以看到,第一大股东是贝莱德股份有限公司,持有5.5%的流通股。伊利金SNT股份有限公司是第二大股东,持有4.0%的普通股,FMR LLC持有约3.4%的公司股份。
更深入地研究我们的所有权数据就会发现,前25名股东总共持有的股份不到登记册的一半,这表明有一大群小股东,没有单一股东占多数。
虽然研究一家公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向也是有意义的。有很多分析师在追踪这只股票,所以他们的预测可能也是值得的。
金色制药的内部人所有权
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
大多数人认为内部人持股是积极的,因为它可以表明董事会与其他股东很好地结盟。然而,在某些情况下,太多的权力集中在这个群体中。
我们可以报告,内部人士确实持有aurinia制药公司的股份。内部人士持有价值1800万美元的可观股份。大多数人会认为这是一个真正的积极因素。如果你想探讨内部人结盟的问题,你可以点击这里,看看内部人是一直在买入还是卖出。
一般公有制
普通公众通常是个人投资者,他们持有aurinia PharmPharmticals 57%的大量股份,这表明它是一只相当受欢迎的股票。这种规模的所有权赋予了来自普通公众的投资者一些集体权力。他们能够而且很可能确实会影响高管薪酬、股息政策和拟议中的企业收购的决策。
接下来的步骤:
虽然考虑拥有一家公司的不同集团是很值得的,但还有其他更重要的因素。以风险为例-Auinia制药公司1个警告标志我们认为你应该意识到。
如果你像我一样,你可能会想一想这家公司是会增长还是会萎缩。幸运的是,您可以查看这份显示分析师对其未来预测的免费报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧